|
1
|
Cragg MS, Kuroda J, Puthalakath H, Huang
DC and Strasser A: Gefitinib-induced killing of NSCLC cell lines
expressing mutant EGFR requires BIM and can be enhanced by BH3
mimetics. PLoS Med. 4:1681–1689; discussion 1690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L,
Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, et al: Epidermal growth
factor receptor mutations and their correlation with gefitinib
therapy in patients with non-small cell lung cancer: a
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu Y, Liu H, Chen J and Zhou Q: Acquired
resistance of lung adenocarcinoma to EGFR-tyrosine kinase
inhibitors gefitinib and erlotinib. Cancer Biol Ther. 9:572–582.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosell R, Taron M, Sanchez JJ and Paz-Ares
L: Setting the benchmark for tailoring treatment with EGFR tyrosine
kinase inhibitors. Future Oncol. 3:277–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Costa DB, Halmos B, Kumar A, Schumer ST,
Huberman MS, Boggon TJ, Tenen DG and Kobayashi S: BIM mediates EGFR
tyrosine kinase inhibitor-induced apoptosis in lung cancers with
oncogenic EGFR mutations. PLoS Med. 4:1669–1679; discussion 1680.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uramoto H, Uchiumi T, Izumi H, Kohno K,
Oyama T, Sugio K and Yasumoto K: A new mechanism for primary
resistance to gefitinib in lung adenocarcinoma: the role of a novel
G796A mutation in exon 20 of EGFR. Anticancer Res 27 (4B).
2297–2303. 2007.
|
|
7
|
Park J, McDonald JJ, Petter RC and Houk
KN: Molecular dynamics analysis of binding of kinase inhibitors to
WT EGFR and the T790M mutant. J Chem Theory Comput. 12:2066–2078.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takeda M, Okamoto I and Nakagawa K:
Survival outcome assessed according to tumor response and shrinkage
pattern in patients with EGFR mutation-positive non-small-cell lung
cancer treated with gefitinib or erlotinib. J Thorac Oncol.
9:200–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Inukai M, Toyooka S, Ito S, Asano H,
Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, et al:
Presence of epidermal growth factor receptor gene T790M mutation as
a minor clone in non-small cell lung cancer. Cancer Res.
66:7854–7858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Onitsuka T, Uramoto H, Nose N, Takenoyama
M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to
gefitinib: the contribution of mechanisms other than the T790M,
MET, and HGF status. Lung Cancer. 68:198–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET
amplification occurs with or without T790M mutations in EGFR mutant
lung tumors with acquired resistance to gefitinib or erlotinib.
Proc Natl Acad Sci USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yano S, Wang W, Li Q, Matsumoto K,
Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka
Y, et al: Hepatocyte growth factor induces gefitinib resistance of
lung adenocarcinoma with epidermal growth factor
receptor-activating mutations. Cancer Res. 68:9479–9487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Velling T, Stefansson A and Johansson S:
EGFR and beta1 integrins utilize different signaling pathways to
activate Akt. Exp Cell Res. 314:309–316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ju LX, Zhou CC, Tang L, Zhao YM, Yang XJ,
Su B, Meng SY, Li W, Yan LH and Ding YM: Drug resistance mechanism
of non small cell lung cancer PC9/AB2 cell line with acquired drug
resistance to gefitinib. Zhonghua Jie He He Hu Xi Za Zhi.
33:354–358. 2010.(In Chinese). PubMed/NCBI
|
|
16
|
Al-Temaimi R, Kapila K, Al-Mulla FR,
Francis IM, Al-Waheeb S and Al-Ayadhy B: Epidermal growth factor
receptor mutations in nonsmall cell lung carcinoma patients in
Kuwait. J Cytol. 33:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kwak EL, Sordella R, Bell DW,
Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR,
Fidias P, Lynch TJ, et al: Irreversible inhibitors of the EGF
receptor may circumvent acquired resistance to gefitinib. Proc Natl
Acad Sci USA. 102:7665–7670. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herbst RS, Johnson DH, Mininberg E,
Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD,
Truong MT, et al: Phase I/II trial evaluating the anti-vascular
endothelial growth factor monoclonal antibody bevacizumab in
combination with the HER-1/epidermal growth factor receptor
tyrosine kinase inhibitor erlotinib for patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:2544–2555. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morgillo F, D'Aiuto E, Troiani T,
Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F and
Ciardiello F: Antitumor activity of bortezomib in human cancer
cells with acquired resistance to anti-epidermal growth factor
receptor tyrosine kinase inhibitors. Lung Cancer. 71:283–290. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park IH, Kim JY, Jung JI and Han JY:
Lovastatin overcomes gefitinib resistance in human non-small cell
lung cancer cells with K-Ras mutations. Invest New Drugs.
28:791–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
